Abstract: Methods, systems, and devices for wireless communications are described. A user equipment (UE) may receive a downlink message which may include an indication of a precoder applied to one or more downlink signals. The UE may receive the one or more downlink signals using a demodulation reference signal (DMRS) and the precoder, where the one or more downlink signals may be mismatched in gain and phase. The UE may perform an iterative channel estimation procedure to estimate the downlink channel. The UE may then perform a gain and phase mismatch equalization procedure to equalize an estimated gain and phase mismatch of the one or more downlink signals based on the estimated downlink channel and the precoder. The UE may then receive one or more equalized downlink signals in accordance with the gain and phase mismatch equalization procedure.

Abstract: Methods, systems, and devices for wireless communications are described. A user equipment (UE) may receive a reference signal from a network entity. The UE may transmit, to the network entity, an estimation of a frequency domain imbalance between an in-phase portion of the reference signal and a quadrature-phase portion of the reference signal based on a precoding matrix associated with transmissions from the network entity and an estimation of one or more channel conditions between the UE and the network entity. The network entity may perform an imbalance compensation operation that balances the in-phase portion and the quadrature-phase portion of the transmission chain based on the estimation of the frequency domain imbalance. The UE may receive, from the network entity, a data transmission based on transmitting the indication of the estimation of the frequency domain imbalance.

Abstract: Described herein are compositions and methods of using single-cell RNA-sequencing to identify treatment resistance in patients with ovarian cancer. Also, described herein are compositions and methods for treatment targeting resistance in patients with ovarian cancer.

Abstract: Methods, systems, and devices for wireless communications are described. A user equipment (UE) may receive a downlink message which may include an indication of a precoder applied to one or more downlink signals. The UE may receive the one or more downlink signals using a demodulation reference signal (DMRS) and the precoder, where the one or more downlink signals may be mismatched in gain and phase. The UE may perform an iterative channel estimation procedure to estimate the downlink channel. The UE may then perform a gain and phase mismatch equalization procedure to equalize an estimated gain and phase mismatch of the one or more downlink signals based on the estimated downlink channel and the precoder. The UE may then receive one or more equalized downlink signals in accordance with the gain and phase mismatch equalization procedure.

Abstract: The subject matter disclosed herein is generally directed to modulating T cell dysfunctional and effector states by modulating glucocorticoid and IL-27 signaling. The invention further relates to modulating immune states, such as CD8 T cell immune states, in vivo, ex vivo and in vitro. The invention further relates to diagnostic and screening methods.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may receive, from a network node, an indication of a phase noise power level associated with the network node. The UE may receive, from the network node, a communication without applying phase noise correction associated with the communication based at least in part on the phase noise power level and one or more conditions being satisfied. Numerous other aspects are provided.

Abstract: The subject matter disclosed herein is generally directed to detecting and modulating novel gene signatures for the treatment and prognosis of cancer. The novel gene signatures predict overall survival in cancer and can be targeted therapeutically.

Abstract: The present invention generally relates to a controlled fluidic device to develop spatially complex environments to enhance the rate of evolution in cell populations. The method further provides an enhanced understanding in the emergence, for example, drug resistance during cancer chemotherapy.

Abstract: This invention relates generally to compositions and methods for modulating complement component 3 (C3) activity or expression to treat, control or otherwise influence tumors and tissues, including cells and cell types of the tumors and tissues, and malignant, microenvironmental, or immunologic states of the tumor cells and tissues. The invention also relates to methods of diagnosing, prognosing and/or staging of tumors, tissues and cells.

Abstract: Described herein are pancreatic ductal adenocarcinoma (PDAC) signatures and methods of detecting the same in a sample from heterogeneity-score a subject. Also described herein, are methods of methods of diagnosing, prognosing, and/or treating PDAC in a subject that can include detecting one or more of the PDAC signatures.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may receive, from a network node, an indication of a non-linearity level associated with transmit antennas of the network node. The UE may selectively perform non-linearity correction for a downlink communication received from the network node based at least in part on the indication of the non-linearity level. Numerous other aspects are described.

Abstract: Described herein are methods for suppressing an immune response in a subject, e.g., a subject with an autoimmune disease, by administering to the subject a therapeutically effective amount of recombinant CD5L, CD5L homodimers and/or CD5L:p40 heterodimers, or nucleic acids encoding any of these. Also described are methods for enhancing an immune response in a subject, e.g., a subject with cancer, infection, or an immune deficiency, by administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds specifically to CD5L, D5L homodimers and/or CD5L:p40 heterodimers, and inhibits their binding to the IL-23 receptor, or inhibits formation of the CD5L homodimer and/or CD5L:p40 heterodimer, or inhibitory nucleic acids that target CD5L and/or p40.

Abstract: The present disclosure is directed to methods of screening for pathological mechanisms in neurodevelopmental and neuropsychological disorders using brain organoids. The present disclosure is also directed to methods of screening agents using the brain organoids.

Abstract: Certain aspects of the present disclosure provide a method for wireless communications by a network entity. The method may include receiving an indication indicating a subset of one or more precoding matrix vectors associated with an estimated channel between a user equipment (UE) and the network entity. The subset of one or more precoding matrix vectors are part of a precoding matrix. The method may include calculating remaining precoding matrix vectors for the precoding matrix, based on the subset of one or more precoding matrix vectors. The method may include generating the precoding matrix based on the subset of one or more precoding matrix vectors and the remaining precoding matrix vectors. The method may include performing precoding of a downlink transmission based on the precoding matrix.

Abstract: The application relates to methods and systems for proteomics and spatial mapping of biomolecules using a next generation sequencing readout to decipher biomolecular and cellular interaction networks. Specifically, disclosed are antenna networks generated by conjugating DNA antennas to proteins. The antennas carry a unique antenna identifier (UAI) sequence that can provide spatial location of the network, as well as biomolecules by transfer of the UAI to reporter oligonucleotides associated with other antennas and biomolecules. The methods and systems are also applicable to single cells.

Abstract: The subject matter disclosed herein is generally directed to modulating anti-tumor T cell immunity by modulating steroidogenesis. Steroidogenesis may be modulated with inhibitors of enzymes that synthesize glucocorticoids in a tumor. The inhibitor may target Cyp11a1. The inhibitor may be metyrapone. The invention further relates to modulating immune states, such as CD8 T cell immune states, in vivo, ex vivo and in vitro. The invention further relates to diagnostic and screening methods.

Abstract: Compositions and systems comprising a dorsal forebrain organoid having a core comprising less than 25% apoptotic or hypoxic cells and one or more tumor cells in the organoid.

Abstract: The present invention discloses antibodies capable of binding to and neutralizing SARS-CoV-2 and variants thereof. The invention also discloses a cell-free antibody engineering platform capable of identifying antibodies that bind to specific target molecules and virus-neutralizing antibodies.

Abstract: Methods, systems, and devices for wireless communications are described. A user equipment (UE) may monitor for a demodulation reference signal (DMRS) according to a default precoder, where the DMRS is associated with channel state feedback (CSF) information. The UE may perform a channel estimation based on the DMRS, and transmit an uplink message indicating one or more candidate precoders, where the one or more candidate precoders are selected based on the channel estimation. The UE may receive a downlink message indicating a precoder of the one or more candidate precoders based on transmitting the uplink message. The UE may then communicate with a network entity in accordance with the indicated precoder based on receiving the downlink message.

Abstract: The present invention discloses novel methods, compositions, and uses thereof for removing or overcoming immunosuppression. More specifically, the methods and compositions disclosed herein target effector Treg cells by modulating ST2 and/or IL-33 signaling using pharmaceutical inhibitors and/or genetic ablation, whereby the levels and/or activities of effector Treg cells in a tumor microenvironment are inhibited, and the infiltration of effector CD8+ cytotoxic T cells into tumor microenvironment increases. As a result, tumor growth is inhibited and tumor volume is reduced. The present invention also provides methods for identifying and isolating effector Treg cells in a population of heterogeneous cells.